HOME ABOUT US TECHNOLOGIES PRODUCT PIPELINE LEAD COMPOUND INVESTORS CAREERS CONTACT

Overview

Advanomics Corporation is a biopharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer.

Advanomics was incorporated on February 28, 2002 under the Canada Business Corporations Act. Our current operations consist of research and development activities including clinical trials to advance drug candidates through the product development and regulatory processes to obtain marketing approval.

Cancer is one of the leading causes of death around the world. Nearly 1.5 million new cases of Cancer are diagnosed annually in the US (www.cancer.org). The cost of cancer therapy worldwide surpassed $40 billion in 2008 (www.marketresearch.com).

Our lead compound, Difluoro-Etoposide™ (Adva-27a), a multi-purpose anti-tumor compound, is expected to enter Phase I clinical trials in Canada later this year.